Scientific papers on CBD and cancer

​

• CBD as potential anticancer drug;

• CBD inhibits angiogenesis by multiple mechanisms;

• The inhibitory effects of CBD on systemic malignant tumors;

• CBD inhibits cancer cell invasion via upregulation of tissue inhibitor of  matrix metalloproteinases-1;

• Marijuana fights cancer and helps manage side effects;

• In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma;

• The influence of biomechanical properties and cannabinoids on tumor invasion;

• Antitumorigenic targets of cannabinoids - current status and implications;

• Cannabinoids - a new weapon against cancer?;

• CBD, a novel inverse agonist for GPR12;

• See more abstracts on specific types of cancer.

​

​

​

 

Scientific papers on CBD and sleep problems

​

• Effects of acute systemic administration of CBD on sleep-wake cycle in rats;

• Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morningbehavior in young adults;

• CBD modulates sleep in rats;

• Endocannabinoid modulation of cortical up-states and NREM sleep;

• Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat;

• Endocannabinoid Signaling Regulates Sleep Stability;

• Cannabis, Cannabinoids, and Sleep: a Review of the Literature;

• Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report;

​

 

Scientific papers on CBD and anxiety

​

• CBD as an anxiolytic drug;

• Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa;

• CBD reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients;

• Neural basis of anxiolytic effects of CBD in generalized social anxiety disorder;

• Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation;

• Effects of CBD on regional cerebral blood flow;

• The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors;

• The anxiolytic effect of CBD on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system;

• Plant-based medicines for anxiety disorders, part 2;

• A systematic review of plant-derived natural compounds for anxiety disorders;

• The Endocannabinoid System and Anxiety;

• CBD regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders;

• Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding

       in the light-dark emergence test in rats;

• Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report.;

• CBD Does Not Dampen Responses to Emotional Stimuli in Healthy Adults;

• Plasma and brain pharmacokinetic profile of CBD, CBDV, THCV and CBG in rats and mice following oral and intraperitoneal administration and

       CBD action on obsessive-compulsive behavior;

• Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives;

• Current status and prospects for cannabidiol preparations as new therapeutic agents.

​

 

 

Scientific papers on CBD and bowel and digestive disorders

​

• CBD in inflammatory bowel diseases: a brief overview;

• Cannabis finds its way into treatment of Crohn’s disease;

• CBD reduces intestinal inflammation through the control of neuroimmune axis;

• Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis;

• The effects of Delta-tetrahydrocannabinol and CBD alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis;

• Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice;

• Cannabinoids and the gut: New developments and emerging concepts;

• Endocannabinoids and the gastrointestinal tract;

• Cannabinoids and gastrointestinal motility: Animal and human studies;

• Hergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis;

• Manipulation of the endocannabinoid system in colitis: A comprehensive review;

• Low-dose cannabidiol is safe but not effective in the treatment for Crohn's Disease, a randomized controlled trial;

• Cannabidiol in inflammatory bowel diseases: A brief overview;

• CBD reduces intestinal inflammation through the control of neuroimmune axis;

• Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine,

        fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?;

• Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation;

• Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease;

• Endocannabinoids and the gastrointestinal tract;

• CBD and gastrointestinal motility;

• Getting into the weed: the role of the endocannabinoid system in the brain-gut axis;

• Cannabinoids and GI disorders: Endogenous and exogenous.

​

​

​

Scientific papers on CBD and Parkinson’s disease

​

• Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial;

• Prospects for cannabinoid therapies in basal ganglia disorders;

• Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease:

       Importance of antioxidant and cannabinoid receptor-independent properties;

• Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease;

• Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder

       in Parkinson’s disease patients

• Cannabidiol for the treatment of psychosis in Parkinson’s disease

• Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease

• Therapeutic potential of cannabinoids in CNS disease

• CB2 Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic

       Neurodegeneration in Rotenone Model of Parkinson's Disease;

• Neurological aspects of medical use of CBD.

​

​

​

​

 

 

Science abstracts on CBD and pain

​

• Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain;

• Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain;

• Cannabis, pain, and sleep: Sativex Clinical Trials;

• Sativex successfully treats neuropathic pain characterised by allodynia: clinical trial;

• Cannabinoids for neuropathic pain;

• Neuropathic orofacial pain: Cannabinoids as a therapeutic avenue;

• Oromucosal delta9-THC/CBD for neuropathic pain associated with multiple sclerosis;

• The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain;

• Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation;

• Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy;

• Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain;

• Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action;

• Cannabinoids suppress inflammatory and neuropathic pain by targeting a3 glycine receptors;

• Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes;

• Cannabinoids in the management of difficult to treat pain;

• Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy,

       safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain;

• Marijuana extract helps prevent chemo pain;

• Pot users less likely to take painkillers;

• CBD & THC interactions on acute pain and locomotor activity;

• CBD is a potential therapeutic for the affective-motivational dimension of incision pain in rats.

​

 

Scientific papers on CBD and inflammation

​

• Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress;

• The endocannabinoid system: an emerging key player in inflammation;

• Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice;

• Cannabinoids, endocannabinoids, and related analogs in inflammation;

• Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute

       lung injury: role for the adenosine A(2A) receptor;

• Cannabinoids suppress inflammatory and neuropathic pain by targeting a3 glycine receptors;

• Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis;

• Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation;

• Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement;

• Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption;

• Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation;

• Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death;

• Cannabinoids in clinical practice;

• Pure THC-V inhibits nitrite production in murine peritoneal macrophages;

• Cannabinoids, inflammation, and fibrosis;

• Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids;

• Endocannabinoid 2-arachidonoylglycerol protects inflammatory insults from sulfur dioxide inhalation via cannabinoid receptors in the brain;

• Protective effect of CBD on hydrogen peroxide-induced apoptosis, inflammation and oxidative stress in nucleus pulposus cells;

• Mechanisms of action of CBD in adoptively transferred experimental autoimmune encephalomyelitis.

​

Scientific papers on CBD and heart disease

​

• Study: History of cannabis use associated with increased survival rates among heart attack patients;

• CBD as an anti-arrhythmic, the role of the CB1 receptors;

• Is the cardiovascular system a therapeutic target for CBD?;

• Acute administration of CBD in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion;

• CBD attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy;

• The effect of CBD on ischemia/reperfusion-induced ventricular arrhythmias;

• CBD protects against myocardial ischemic reperfusion injury;

• Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension;

• Oleamide: A fatty acid amide signaling molecule in the cardiovascular system?;

• Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis;

• The role of the endocannabinoid system in atherosclerosis;

• Cannabinoid receptors in atherosclerosis;

• The potential use of cannabidiol in the therapy of metabolic syndrome.

​

​

​

Scientific papers on CBD and depression

​

• Endocannabinoid system dysfunction in mood and related disorders;

• Antidepressant-like and anxiolytic-like effects of CBD;

• The endocannabinoid system and the treatment of mood and anxiety disorders;

• Endocannabinoid signaling in the etiology and treatment of major depressive illness;

• Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors;

• >Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants;

• Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa;

• Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress;

• Serum contents of endocannabinoids are correlated with blood pressure in depressed women;

• The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants;

• Antidepressants and changes in concentration of endocannabinoids and n-acylethanolamines in rat brain structures;

• Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors;

• Prohedonic effect of CBD in a rat model of depression;

• Antidepressant-like and anxiolytic-like effects of CBD.

​

​

Scientific papers on CBD and Alzheimer's & dementia

​

• Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s disease;

• The therapeutic potential of the endocannabinoid system for Alzheimer’s disease;

• Endocannabinoid signalling in Alzheimer’s disease;

• A molecular link between the active component of marijuana and Alzheimer’s disease pathology;

• Neuroprotective effect of CBD… on beta-amyloid-induced toxicity in PC12 cells;

• The Potential Therapeutic Effects of THC on Alzheimer’s Disease;

• The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer’s Disease;

• Cannabinoids for the treatment of dementia;

• CBD in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression;

• CBD: A promising drug for neurodegenerative disorders?;

• Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer’s disease leads to enhanced cognitive impairment

       despite of a reduction in amyloid deposition;

• The role of the endocannabinoid system in Alzheimer’s disease;

• The role of phytochemicals in the treatment and prevention of dementia;

• Cannabinoids for the treatment of dementia;

• Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of

       Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement;

• Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic;

• Can Marijuana Prevent Alzheimer’s?;

• Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia;

• Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview;

• Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model;

• CBD Modulates the Expression of Alzheimer’s Disease-Related Genes in Mesenchymal Stem Cells;

• In vivo Evidence for Therapeutic Properties of CBD for Alzheimer's Disease;

• Neurological aspects of medical use of CBD;

​

​

​

Scientific papers on CBD and diabetes

​

• The impact of marijuana use on glucose, insulin, and insulin resistance among US adults;

• CBD attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy;

• CBD lowers incidence of diabetes in non-obese diabetic mice;

• Neuroprotective and blood-retinal barrier-preserving effects of CBD in experimental diabetes;

• Cannabidiol arrests onset of autoimmune diabetes in NOD mice;

• Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation;

• Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes;

• The endocannabinoid system in obesity and type 2 diabetes;

• Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes;

• The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications;

• Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain;

• Biochemical and immunohistochemical changes in delta-9-tetrahydrocannabinol-treated type 2 diabetic rats;

• Efficacy and safety of CBD and THC-V on glycemic and lipid parameters in patients With Type 2 diabetes.

​

Scientific papers on CBD and ADD & ADHD

​

• Searching for a Neurobiological Basis for Self-Medication Theory in ADHD Comorbid With Substance Use Disorders;

• CBD and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats;

• Subtypes of ADHD and cannabis use;

• Childhood and current ADHD symptom dimensions are associated with more severe cannabis outcomes in college students;

• Oral delta 9-THC improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition;

• Fitness to drive in spite (because) of THC;

• ADHD Is Highly Prevalent in Patients Seeking Treatment for Cannabis Use Disorders;

• A Qualitative Analysis of Online Forum Discussions on Cannabis Use and ADHD;

• Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial.